Summary of Study ST000995

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000675. The data can be accessed directly via it's Project DOI: 10.21228/M8DX19 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis | Show all samples | Show named metabolites | Download named metabolite data
Download mwTab file (text) | Download mwTab file(JSON)

Study ID	ST000995
Study Title	Amino Acid Concentrations of Primary Sclerosing Cholangitis (part I)
Study Summary	To qualitatively and quantitatively analyze enterohepatically-circulated molecules using targeted amino acid concentrations of peripheral blood collected from primary sclerosing cholangitis (PSC) patients compared to normal and diseased controls. There are three groups of patients. (1) Normal donor controls (ND), (2) Patients with Primary Sclerosing Cholangitis (PSC), and (3) Disease Controls (DC) which are patients with liver disease other than PSC.
Institute	Mayo Clinic
Last Name	O'Hara
First Name	Steven
Address	200 First St. SW, Rochester, Minnesota, 55905, USA
Email	ohara.steven@mayo.edu
Phone	507-284-1006
Submit Date	2018-07-05
Raw Data Available	Yes
Raw Data File Type(s)	raw(Thermo)
Analysis Type Detail	LC-MS
Release Date	2019-07-17
Release Version	1

Select appropriate tab below to view additional metadata details:

Treatment:

Treatment ID:	TR001048
Treatment Summary:	We prospectively enrolled three groups of participants from the Mayo Clinic Liver Transplant inpatient service and outpatient clinics and have collected samples from: i) 9 patients with PSC who underwent living- donor LT, ii) 15 donors (normal controls), and iii) 20 patients with cirrhosis due to a disorder other than PSC who underwent LT (disease controls). The following inclusion and exclusion criteria were applied: Inclusion criteria 1. Adult (age>18 years). 2. PSC patient undergoing LT, healthy living donor, or other chronic liver disease patient undergoing LT. Exclusion Criteria: 1. Females who are pregnant or attempting to become pregnant. 2. Concomitant liver disease (e.g. chronic viral hepatitis in addition to PSC). 3. Acute intestinal disease (infectious enterocolitis, IBD flare) in the past 6 months. 4. Treatment with any investigational drugs within the past 6 months. 5. Use of antibiotics within the past 4 weeks. 6. Any previous organ transplant. 7. Hemodialysis.

Treatment ID:

TR001048

Treatment Summary:

We prospectively enrolled three groups of participants from the Mayo Clinic Liver Transplant inpatient service and outpatient clinics and have collected samples from: i) 9 patients with PSC who underwent living- donor LT, ii) 15 donors (normal controls), and iii) 20 patients with cirrhosis due to a disorder other than PSC who underwent LT (disease controls). The following inclusion and exclusion criteria were applied: Inclusion criteria 1. Adult (age>18 years). 2. PSC patient undergoing LT, healthy living donor, or other chronic liver disease patient undergoing LT. Exclusion Criteria: 1. Females who are pregnant or attempting to become pregnant. 2. Concomitant liver disease (e.g. chronic viral hepatitis in addition to PSC). 3. Acute intestinal disease (infectious enterocolitis, IBD flare) in the past 6 months. 4. Treatment with any investigational drugs within the past 6 months. 5. Use of antibiotics within the past 4 weeks. 6. Any previous organ transplant. 7. Hemodialysis.